Sayeh Nikpay
Biographic Data
| ID | 6638655 |
|---|---|
| NAME | Sayeh Nikpay |
| GIVEN NAMES | Sayeh |
| FAMILY NAME | Nikpay |
| SIGNATURE | NIKPAY S |
| AFFILIATIONS | University of Minnesota |
| ORCID | 0000-0002-0334-0743 |
| VERIFIED | Yes |
| TOTAL WORKS | 9 |
| TOTAL CITATIONS | 1 |
| AUTHOR COUNT | 9 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2016 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 1 |
Minnesota Law Brings Transparency to the 340B Drug Pricing Program
This Viewpoint discusses the need for visibility into results of the federal 340B Drug Pricing Program and reviews first data from Minnesota
Characteristics of 340B Hospitals Receiving Medicare Part B Repayments
This cross-sectional study compared the characteristics of 340B hospitals that did not receive a lump sum payment with hospitals in the program that did receive payment
B Participation and Safety Net Engagement Among Federally Qualified Health Centers
The results of this cohort study suggest that there are statistically significant increases in the provision of low-profit but high-value preventive services and care to safety net populations (those who lack insurance, have a low income, or require enabling services) and that, like public hospitals, FQHCs might use 340B revenues to enhance safety net care. This finding may inform debates on the 340B program by supporting differential 340B reform…
Public Hospitals May Use the 340B Program Differently Than Nonprofit Hospitals
Kelsey M. Owsley, PhD; Romana Hasnain-Wynia, PhD; Ronica N. Rooks, PhD; Gregory J. Tung, PhD; Glen P. Mays, PhD; Richard C. Lindrooth, PhD
Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022
This cross-sectional study assesses the increases and decreases over time in the number of pharmacy contracts, distance from contracting pharmacies, and proportion of pharmacy contracts with safety-net practices in the US
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population
Trends in Ransomware Attacks on US Hospitals, Clinics, and Other Health Care Delivery Organizations, 2016-2021
This cohort study of ransomware attacks documented growth in their frequency and sophistication. Ransomware attacks disrupt care delivery and jeopardize information integrity. Current monitoring/reporting efforts provide limited information and could be expanded to potentially yield a more complete view of how this growing form of cybercrime affects the delivery of health care
Federal Support for Family Planning Clinics Associated with Dramatic Gains in Cervical Cancer Screening
Health Reform and Retirement
Although many observers had predicted that an unintended consequence of health reform would be reduced labor supply, we find no evidence of this for older workers in the first 2.5 years after the law's major coverage provisions took effect
Health Reform and Retirement
Although many observers had predicted that an unintended consequence of health reform would be reduced labor supply, we find no evidence of this for older workers in the first 2.5 years after the law's major coverage provisions took effect
Federal Support for Family Planning Clinics Associated with Dramatic Gains in Cervical Cancer Screening
Health Reform and Retirement
Although many observers had predicted that an unintended consequence of health reform would be reduced labor supply, we find no evidence of this for older workers in the first 2.5 years after the law's major coverage provisions took effect
Trends in Ransomware Attacks on US Hospitals, Clinics, and Other Health Care Delivery Organizations, 2016-2021
This cohort study of ransomware attacks documented growth in their frequency and sophistication. Ransomware attacks disrupt care delivery and jeopardize information integrity. Current monitoring/reporting efforts provide limited information and could be expanded to potentially yield a more complete view of how this growing form of cybercrime affects the delivery of health care
Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022
This cross-sectional study assesses the increases and decreases over time in the number of pharmacy contracts, distance from contracting pharmacies, and proportion of pharmacy contracts with safety-net practices in the US
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population
Characteristics of 340B Hospitals Receiving Medicare Part B Repayments
This cross-sectional study compared the characteristics of 340B hospitals that did not receive a lump sum payment with hospitals in the program that did receive payment
B Participation and Safety Net Engagement Among Federally Qualified Health Centers
The results of this cohort study suggest that there are statistically significant increases in the provision of low-profit but high-value preventive services and care to safety net populations (those who lack insurance, have a low income, or require enabling services) and that, like public hospitals, FQHCs might use 340B revenues to enhance safety net care. This finding may inform debates on the 340B program by supporting differential 340B reform…
Public Hospitals May Use the 340B Program Differently Than Nonprofit Hospitals
Kelsey M. Owsley, PhD; Romana Hasnain-Wynia, PhD; Ronica N. Rooks, PhD; Gregory J. Tung, PhD; Glen P. Mays, PhD; Richard C. Lindrooth, PhD
Minnesota Law Brings Transparency to the 340B Drug Pricing Program
This Viewpoint discusses the need for visibility into results of the federal 340B Drug Pricing Program and reviews first data from Minnesota
Business (9 works) · Medicine (8 works) · Actuarial science (4 works) · Family medicine (4 works) · Healthcare Policy and Management (4 works) · Pharmaceutical Economics and Policy (4 works) · Political science (3 works) · Computer Science (2 works) · Drug pricing (2 works) · Economics (2 works)